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1 Drug description 
Generic/Brand name:  
Lapatinib ditosylate (Tyverb® - Europe/Tykerb® – U.S.) 
Developer/Company:  
Glaxo Group Limited 
Description:  
The active substance of Tyverb®/Tykerb® is lapatinib ditosylate monohy-
drate which belongs to the group of protein kinase inhibitors.  The mecha-
nism of action is the inhibition of the intracellular tyrosine kinase domain of 
Epidermal Growth Factor Receptor (EGFR [ErbB1]) and of Human Epi-
dermal Growth Factor Receptor 2 (HER2 [ErbB2]) receptors [1, 2] which 
demonstrated (in vitro, animal models) an inhibition of ErbB-driven tumour 
growth [1].  
Tyverb®/Tykerb® is available in 250mg tablets. The recommended dosing 
regimen for the treatment of HER2+, advanced/metastatic progressive 
breast cancer is 1,250mg daily, corresponding to 5 tablets orally, continu-
ously. Lapatinib should be taken in combination with capecitabine 
2,000mg/m²/day administered in 2 doses and a 12 hour interval on days 1 
and 14 in a 21 days cycle [2].  
For HER2+, hormone receptor (HR) positive, metastatic breast cancer 
(MBC), 1,500mg Tyverb®/Tykerb®  daily are recommended in addition to 
2.5mg letrozole [1]. 
As observed side-effects include a decrease in left ventricular ejection frac-
tion, pulmonary toxicity and hepatotoxicity, control of this parameters prior 
to, and monitoring during, treatment with lapatinib is indicated [2].  
2 Indication 
Lapatinib ditosylate (Tyverb®/Tykerb®) is indicated for the treatment of pa-
tients with advanced/metastatic breast cancer (BC) who have not received 
prior chemotherapy for the treatment of their advanced disease.  
lapatinib inhibits 
intracellular tyrosine 
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3 Current regulatory status 
The EM(E)A granted market authorization for Tyverb®,  
 in combination with capecitabine for the treatment of patients with 
HER2 over-expressing advanced or metastatic BC whose disease 
should have progressed following prior therapy (including anthra-
cyclines and taxanes and therapy with trastuzumab) in the metas-
tatic setting in June 2008 [2]. EM(E)As market authorization is 
based on a “conditional approval” scheme where further evidence is 
awaited and newly generated data are reviewed annually. 
 “for patients with HER2 over-expressing tumours in combination 
with an aromatase inhibitor for postmenopausal women with HR+ 
metastatic disease, not currently intended for chemotherapy in May 
2010. The patients in the registration study were not previously 
treated with trastuzumab or an aromatase inhibitor [3].” 
In the U.S., the FDA licensed Tykerb® for  
 the treatment of patients with HER2 over-expressing advanced or 
metastatic BC in combination with capecitabine after prior therapy 
including anthracyclines, taxanes or trastuzumab in March 2007. 
 for postmenopausal women with HR+, HER2 over-expressing 
MBC in combination with letrozole when hormonal therapy is in-
dicated in January 2010 [1].  
4 Burden of disease 
In 2007, about 4,600 women were diagnosed with and 1,550 died of BC in 
Austria [4] making breast cancer the most common type of cancer in females 
with more than 80% of all cases of cancer occurring in women aged over 50 
years [5]. Risk factors associated with the development of BC are age, family 
history, nulliparity, early menarche or genetic factors (e.g genetic mutations 
such as of the BRCA1, BRCA2) [6, 7].  
Prognostic factors are age, menopausal status, tumour stage, histology, hor-
mone receptor status, clinical response and lymph node status after induc-
tion therapy, out of which clinical response to initial treatment and lymph 
node status are the most important ones [6].  
The Tumor Node Metastasis (TNM) staging classification is used to deter-
mine the disease stage. This staging system reflects the extent of disease 
which is used to inform management decisions and to determine prognosis 
[6]. Besides the primary tumour, the extent of which the regional lymph 
nodes are involved and the absence or presence of distant metastases are 
taken into account, leading to four main stage groupings (stage I to IV) [6]. 
Advanced BC belongs to stage III, whereas metastatic disease corresponds to 
stage IV. Metastases are most common in the bones, liver or the lungs.  
EM(E)A:  
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Metastatic disease at diagnosis is present in less than 10% of women. [6], but 
the majority of patients, that is about 50%, initially presenting with earlier 
forms of breast cancer, will develop MBC eventually [8]. Evidence suggests  
that 20% to 25% of all women diagnosed with BC have tumours over-
expressing HER2 [9-11], but due to various methods for determining HER2 
status it might be the case that these numbers  are slightly overestimated 
[12].  However, applying these estimates to an Austrian context would result 
in about 100 women with HER2+ advanced MBC. Cure of MBC  and com-
plete remissions after chemotherapy are rare, resulting in a median survival 
of about 18 to 24 months [7] and in only 5 -10% of women who survive five 
or more years [6].  
Besides the TNM staging, more important factors to determine the best 
management strategy are estrogen-receptor (ER) and progesterone-receptor 
(PR) levels in the tumour tissue, HER2 status, menopausal status, and the 
general health of the patient [7]. Predictive factors for response to hormone 
therapy are a long relapse-free interval, isolated bone and soft tissue in-
volvement, and prior response to endocrine therapy. ER+/PR+ tumours are 
most likely to respond to hormone therapy, but even of them, up to 25% are 
refractory to hormone therapy in the first instance and nearly all tumours 
become refractory at one point [6].  
BC with amplification and over-expression of HER2 are usually more ag-
gressive [6, 11] corresponding to a reduced overall survival (OS) and a short-
ened time to relapse [10]. However, HER2 status is used to predict response 
to drugs such as trastuzumab or lapatinib [6], but even then, many patients 
over-expressing HER2 do not respond to HER2-targeted therapies [10, 13]. 
Additionally, primary resistance to endocrine therapy might be associated 
with HER2 over-expression due to a cross-talk between ErbB1/ErbB2 and 
ER pathways. Moreover, a link between responsiveness to chemotherapy and 
HER2 over-expression might exist [6]. 
5 Current treatment 
Choice of therapy for BC is based on numerous factors like tumour histol-
ogy, axillary node status, hormone and HER2 receptor  status, presence of 
metastases as well as patients characteristics including menopausal status, 
age and co-morbidities [9].  
For advanced BC a combined modality approach is regarded as standard of 
care. After determination of histology, ER/PR levels, and HER2 over-
expression by biopsy, options are  
 neoadjuvant chemotherapy: initial treatments are either anthracy-
cline–containing regimens  (e.g. 5-fluorouracil, and cyclophos-
phamide ± doxorubicin/epirubicin) and/or taxane-containing 
therapies (e.g. docetaxel, paclitaxel) [6, 7].  
 locoregional therapy: depends on the tumour response to neoadju-
vant therapy and comprises  
metastatic disease in 
about 10% of women 
HER2 over-expression in 
about 20% of 25% of all 
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o surgery either in form of breast-conserving therapy if a 
good partial or a complete response after neoadjuvant 
chemotherapy was achieved (in about 50%-90% of women) 
[6] or total mastectomy with axillary lymph node dissec-
tion.  
o postoperative radiation therapy: after surgery, to the chest 
wall and regional lymphatics. 
 Adjuvant therapy: if the initial response was a less than complete or 
a good partial response, chemotherapy with non cross-resistant 
drug(s), that is if neoadjuvant therapy included a taxane an anthra-
cycline is indicated and vice-versa. Hormone therapy with ta-
moxifen or an aromatase inhibitor should be administered to pa-
tients whose tumours are ER-positive or unknown.  
 trastuzumab: is indicated either in the adjuvant or in the neoadju-
vant setting if tumours over-express HER2 [6, 9]. 
 capecitabine: is recommended by some guidelines [9] either preop-
eratively or to sensitize for radiation therapy.  
Therapy of MBC usually aims at symptom palliation, improvement of qual-
ity of life (QoL) and extension of  life [7]. Under careful consideration of 
toxicities arising from therapy and the likelihood of achieving palliation, 
available treatment options are: 
 surgery 
 radiation therapy 
 chemotherapy: either single agents (e.g. anthracyclines, taxanes), or 
chemotherapy combinations (e.g. cyclophosphamide/ doxorubi-
cin/fluorouracil) or  chemotherapeutic agents in combination with 
molecular targeted therapies (e.g. bevacizumab/paclitaxel, trastu-
zumab/paclitaxel ± carboplatin [9].  
 hormone therapy: for example tamoxifen, letrozole or fulvestrant 
either neoadjuvant or adjuvant for postmenopausal women when 
the tumour is ER, PR positive or the ER/PR status is unknown [7]. 
Other factors predicting response to endocrine therapy are a long 
relapse-free interval and response to previous endocrine therapies.  
Then, hormone therapy is preferred over chemotherapy as the tox-
icity profile is in favour for the former one [6].  
 molecular targeted therapies:  
o trastuzumab for HER2 overexpressing tumours +/- che-
motherapy (but not with anthracyclines) for tumours re-
fractory to standard endocrine therapy, trastuzumab + 
endocrine therapy for HR+/HER2+ tumours,  























 LBI-HTA | 2010 7 
6 Evidence 
Two phase III trials with different inclusion criteria and different treatment 
regimens were identified [14, 15]. In these trials, lapatinib was administered 
either in addition to paclitaxel or letrozole, and both demonstrated im-
provements for patients with HER+ BC. Adverse events occurred more of-
ten in those groups where lapatinib was given in addition to other drugs, but 
were mostly of grade 1 or grade 2. Results on QoL demonstrated no differ-
ences in the overall population, but a subgroup analyses indicated improved 
QoL scores for a group (n= 86 pts) of HER2+ patients  [14].  
Another trial [16] assessed two different dosing regimens of lapatinib. Here, 
adverse events occurred in up to 70% of all patients out of which 24% were 
classified as serious ones.   
With 64%, a high frequency of adverse events was also shown in a meta-
analysis which incorporated results of three individual studies [17]. Im-
provements in progression-free survival (PFS) as well as in OS were found 
for HER2+ patients, but these results have to be interpreted with caution as 
the sample sizes within the included studies were small. 
6.1 Efficacy and safety - Phase III studies 
 
Reference  EGF30001, published [15]1 EGF30008, published [14, 18]2 
Sponsor GlaxoSmithKline GlaxoSmithKline 
Country multicenter: Italy, Brazil, US, Peru, Pakistan, Lat-
via 
multicenter: UK, US, France, Peru, Russia, Ireland 
Design randomized, double-blind, placebo-controlled, 
phase III 
randomized, double-blind, controlled, parallel group, 
phase III,  
intention-to-treat (ITT) population consisted of hor-
mone receptor (HR)+ patients out of these, 218 pts were 
confirmed being HER2+ 
 
                                                             
1 TTP= time to progression, ORR = objective response rate (= complete or partial re-
sponse confirmed ≥ 4 weeks from first response), CBR = clinical benefit rate (= com-
plete response, partial response, stable disease ≥ 24 weeks), EFS = event free survival, 
OS= overall survival, OR = odds ratio, NA = not available, ECOG = Eastern Coopera-
tive Oncology Group, p.o. = per os, QoL= quality of life, FACT-B= Functional As-
sessment of Cancer Therapy-Breast, TOI = trial outcome index, BCS = breast cancer 
subscale, Q-TWiST = quality-adjusted time without symptoms or toxicity 
2 PFS = progression-free survival, ORR = overall response rate, CBR = clinical benefit 
rate (= complete response (CR) , partial response (PR), stable disease ≥6 months (SD)), 
OS = overall survival, ECOG = Eastern Cooperative Oncology Group, p.o. = per os 
two phase III trials 
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I(ntervention) 291, mean age 51 (range 23-87) 
years, ER+ and or PR+: 44%, ER/PR status un-
known 21% 
C(ontrol): 288, mean age 52 (range 25-78) years, 
ER+ and/or PR+: 50%, ER/PR status unknown: 
16% 
1,286 pts 
I(ntervention): ITT: 642 pts, median age: 62 (range 31-
97) years,  HER2+: 111 pts, median age: 60 (range 44-85) 
years 
C(ontrol):: ITT: 644 pts,  median age 62 (range 35-95) 
years, HER2+: 108  pts, median age 59 (range 45-87) 
years 
Treatments I(ntervention): 1,500 mg lapatinib p.o daily + 
175mg/m2 paclitaxel iv. over 3 hours on day 1, 
every 3 weeks for up to 6 cycles 
 
C(ontrol): placebo + 175mg/m2 paclitaxel iv. over 
3 hours on day 1, every 3 weeks for up to 6 cycles 
I(ntervention): 1,500 mg lapatinib p.o + 2.5 mg letrozole 
p.o. daily until disease progression 
 
C(ontrol): placebo pill + 2.5 mg letrozole p.o. daily until 
disease progression 
                                 
In-/exclusion criteria Inclusion: histologically confirmed stage III or IV 
HER2 negative or untested BC and untreated in 
the metastatic setting, previous therapy with an-
tracyclines, taxanes was allowed + a disease free 
interval of > 6 months was required between 
completion of taxane-based therapy and disease 
relapse/study enrolment, ECOG ≤ 1 
Inclusion: postmenopausal, histologically confirmed 
IIIB/IIIC or IV ER+ ± PR+ invasive BC, antiestrogen, 
aromatase inhibitor and/or trastuzumab therapy com-
pleted > 1 year prior to study entry was allowed, ECOG ≤ 
1 , normal LVEF 
Exclusion: prior therapy for advanced/metastatic BC, ex-
tensive symptomatic visceral disease,  
Follow-up 96 weeks Median: 1.8 years 
Outcomes Primary: TTP 
Secondary: ORR, CBR, duration of response, EFS, 
OS 
Primary: (investigator assessed) PFS in the HER2+ popu-
lation 
Secondary: ORR, CBR, OS, safety for the HER2+ popula-
tion, PFS for the ITT HR+ population 
Key results  
 
Primary: Median TTP: I 29 weeks vs C 22.9 weeks, 
HR= 0.87, 95% CI 0.72 to 1.05, p= 0.14 
 
Secondary:  
- ORR: OR = 1.7, 95% CI 1.1 to 2.4, p= 0.008 
- CBR: OR = 1.5, 95% CI 1.0 to 2.1, p = 0.025 
- EFS + OS (OS after 46% of events occurred) not 
significant 
 
Pre-planned subset analysis in HER2+ subgroup (I 
49 pts C 37 pts): 
 - TTP: I 36.4 weeks vs C 25.1 weeks,  
   HR= 0.53, 95% CI 0.31 to 0.89, p = 0.005 
- CBR: I 69.4% vs C 40.5%, p=0.011 
- EFS: I 35.1 vs C 21.9 weeks 
  HR = 0.52, 95% CI 0.31 to 0.86, p =0.004 
- ORR: 63.3% vs 37.8%, p=0.023 
- OS not statistically significant  
1) HER2+  population 
 Primary:  
- median PFS: I 8.2 months vs C 3.0 months,  HR= 0.71, 
95% CI 0.53 to 0.96, p= 0.019 
 
 Secondary:  
- ORR: I 28% vs C 15%, OR= 0.4, 5% CI 0.2 to 0.9, 
   p=  0.021 
- CBR: I 48% vs C 29%, OR= 0.4, 95% CI 0.2 to 0.8,  
   p =0.003 
- OS: I 33.3 months vs C 32.3 months, HR= 0.74,  
   95% CI 0.5 to 1.1, p= 0.113 (less than 50% of OS events   
recorded)  
 
2) ITT analysis in HR+ population: 
- Median PFS: I 11.9 months vs C 10.8 months,   
  HR= 0.86, 95% CI 0.76 to 0.98, p=0.026 
- CBR + ORR : no statistically significant difference 
QoL [19, 20]  
(according to publica-
tions in addition to ef-
ficacy studies) 
QoL [19]: 
- ITT: QoL scores stable over time in both groups 
with no statistically significant difference 
- post-hoc analyses of HER2+ subgroup: 
FACT-B, TOI, BCS scores significantly more fa-
vourable results for I 
Q-TWiST difference range: 2 to 15 weeks,  favour-
ing I 
QoL in HER2+ population [20]: 
Mean changes in subscale and total QoL stable over time 
in both groups 
quality-adjusted survival difference 8 – 9.5 weeks fa-
vouring I, but not statistically significant 
Adverse effects - treatment discontinuation: I 16% vs C  7% 
- LVEF decrease: I 2% vs C 2% 
- at least one SAE reported (e.g. neutropenia, diar-
rhea): I 35% vs C 22% 
- SAE- related deaths: I 2.7% due to septic shock ± 
diarrhea, cardiac arrest, heart failure vs C 0.6% 
- most common: diarrhea, rash, nausea, arthralgia of 
grade 1 or 2 
- LVEF decline: I 0.8% vs C 0.3% 
- hepatotoxicity: I 8 pts vs C 1 pt 
- any serious adverse event (drug related) I 8% vs C 4% 
- deaths: related to serious adverse events: I 8 pts vs C 8 
pts, related to study drug: I 1 vs C 2 
Commentary primary activity of lapatinib in BC patients is me-
diated through HER2 inhibition 
combination of letrozole and lapatinib significantly en-
hances PFS and CBR rates in MBC patients co-expressing 
HR and HER2 
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One phase III trial [15], comprising 579 patients with HER2- or HER2 un-
characterized MBC compared paclitaxel and lapatinib with paclitaxel plus 
placebo. Overall, improved outcomes for the combination arm were seen for 
ORR and CBR. However, favourable results were found for a pre-planned 
subgroup of retrospectively identified HER2+ patients where increases in 
TTP (11.3 weeks difference), ORR and EFS were observed. Nonetheless, this 
subgroup was with, overall, 86 patients (I 49, C 37) considerably small and 
even the authors themselves state that these results “should be considered as 
hypothesis generating”. For HER- patients, on the other hand, no improve-
ments in any of the outcome measures occurred. With regards to adverse 
events, rash, diarrhae, mucositis and vomiting were overall significantly 
more frequent in the combination arm, as well was the occurrence of at least 
one serious adverse event (I 35% vs C 22%). 16% in the intervention arm 
and 7% in the control group discontinued treatment. Another study [19], 
which had calculated the QoL scores, found no improvements for the whole 
study population but favourable results for the HER2+ group.  
Johnston et al. assessed lapatinib in combination with letrozole in compari-
son to letrozole and placebo [14]. 1,286 HR+, postmenopausal women with 
ECOG status 0 or 1 suffering from MBC and with no prior therapy for the 
metastatic disease were enrolled and formed the intention to treat popula-
tion. Out of these, 219 patients were confirmed as HER2+. Primary outcome 
was PFS in the HER2+ population which showed, after a median follow-up 
of 1.8 years, a difference of 5.2 months in favour of the intervention group. 
Improvements were also found for CBR and ORR, both achieving statistical 
significance. After less than 50% of OS events recorded, OS differed by 1 
month. Improvements in PFS were also found for the intention to treat 
population (HR+ patients), but not for the HER2- group. Some preliminary 
data (full text not yet published) on QoL were presented at the Breast Can-
cer Symposium 2009 but showed no significant differences in between the 
treatment arms [20].  
6.2 Efficacy and safety - further studies 
Gomez et al. evaluated two different dosing regimens of lapatinib, either 
1,500mg once daily or 500mg twice daily in 138 women with HER2 ampli-
fied advanced or metastatic BC [16]. 69 patients were allocated to each 
group, and showed, overall, an ORR of 24% and a median time to response 
of 7.9 weeks. PFS rates at 4 months and 6 months were 63% and 43% respec-
tively. Most common adverse events were grade 1 or grade 2 diarrhea and 
rash. In total, 71% were affected by treatment related side-effects.  Serious 
AEs occurred in 24% with 7% being treatment related which led 7 patients 
to discontinue lapatinib therapy. Out of six deaths, one was considered to be 
due to therapy.  
A meta-analysis incorporated in addition to the aforementioned phase III 
trials another study where patients had previously received other forms of 
therapy [17].  For PFS improved outcomes for HER2+ patients were found 
(HR = 0.61, 95%CI 0.5 to 0.74). The same held true for OS (HR = 0.76, 95% 
CI 0.6 to 0.96) even though the results of the individual studies were not sta-
tistically significant. These findings were not repeated in HER- patients. Pa-
tients treated with lapatinib, however, were 64% more likely to develop any 
side effect and 2.3 times more likely to discontinue treatment. The authors 
lapatinib + paclitaxel in 
comparison to paclitaxel 
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acknowledge, although, that the statistical power of subgroup analysis was 
diminished due to considerably small sample sizes for these groups.  
7 Estimated costs 
One package Tyverb® containing 70 250mg tablets costs € 1,235.- [21]. If 
administered as first-line therapy in the advanced/metastatic disease setting 
and in addition to letrozole, the recommended dose is 1,500 mg daily con-
tinuously. This results in daily costs of € 106 and, accordingly, in monthly 
costs of about € 3,200.  As mentioned above, these expenses occur in addition 
to letrozole, any subsequent therapies as well as costs for HER2 testing.  
8 Ongoing research 
Limiting the search terms on clinicaltrials.gov to “metastatic breast cancer”, 
“first-line” and “lapatinib” yielded one study currently recruiting patients: 
NCT00667251: assesses taxane based chemotherapy with lapatinib or trastu-
zumab for women with HER2+ metastatic breast cancer. Final data collec-
tion for the primary outcome measure PFS is expected to be in July 2011.  
In addition, 20 ongoing phase III were found, evaluating lapatinib in a broad 
variety of indications such as for earlier stages of BC, in combination with 
bevacizumab and everolimus in the neoadjuvant setting or as adjuvant 
treatment in comparison to trastuzumab.  
9 Commentary  
Two phase III trials assessing lapatinib as first-line therapy in the ad-
vanced/metastatic BC disease setting were identified [14, 15]. Di Leo et al., 
evaluated this tyrosine kinase inhibitor in HER2- or HER2 uncharacterized 
patients [15]. Improvements for the whole study population were observed 
for overall response rates and clinical benefit rates, but showed no improve-
ments for any other outcomes. In a retrospectively identified subgroup of 
HER+ women, an increase of time-to-progression by about 11 weeks and for 
event-free survival by about 13 weeks was shown. Nonetheless, this subgroup 
consisted of only 86 patients and was hence considerably small. Accordingly, 
improved QoL outcomes for this subgroup should also be interpreted with 
caution [19]. 
monthly cost of 
lapatinib about € 3,200 
plenty phase III studies 
ongoing  
evaluation of lapatinib 
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Another phase III trial, which formed the basis for FDA’s decision on grant-
ing market authorization for lapatinib for the treatment of postmenopausal 
women with HR+, HER2 over-expressing metastatic breast cancer in com-
bination with letrozole, assessed the TKI in 1,286 postmenopausal women 
with HR+ MBC.  Letrozole was administered either in combination with 
lapatinib or alone. The primary outcome was PFS in HER2+ patients 
(n=219) and showed a difference of about 5 months in favour of the la-
patinib group. OS data were not mature but no differences between the two 
groups have been demonstrated so far. Preliminary data on QoL were pre-
sented for this trial at the Breast Cancer Symposium 2009 and showed no 
differences, neither for the overall population nor for the HER2+ subgroup 
[20].  
In terms of adverse events, both studies showed somehow similar results. 
Most common adverse events of patients receiving lapatinib were of grade 1 
or 2 and included symptoms such as rash, diarrhea or nausea. The only AEs 
of higher grades which occurred in more than 1% of patients were grade 3 
diarrhea (9% of pts), fatigue and back pain (each in 2% of patients). Cardio-
toxicity, an adverse event related to lapatinib, was observed in 2% and 0.8% 
of patients, showing no differences to the control groups. These findings are 
in concordance with data on cardiac toxicity of 18 studies encompassing 
more than 1,600 BC patients where an incidence of 1.8% for a symptomatic 
or asymptomatic decline in left ventricular ejection fraction was reported 
[13]. 
Despite an increase of PFS by 5 months it has to be kept in mind that an in-
crease in PFS must not necessarily translate into gains of OS, as happened 
with bevacizumab where similar gains of PFS did not lead to improvements 
of OS [22, 23]. Moreover, even though PFS in HER2+ patients was primary 
outcome at least in one of the studies, the group of HER2+ individuals was 
with 219 and 86 patients quite small. Additionally, as interaction of signal-
ling pathways of receptors might change receptor status of tumours [6] and 
resistance to lapatinib can either exist in the first place or can develop dur-
ing therapy [13, 24], implications for the suitability of subsequent lines of 
treatment might arise. Hence, predictors of tumour response have to be ex-
plored further to identify patients most likely to benefit from individual 
drugs and to establish the most beneficial sequence of therapies. Also of in-
terest is the direct comparison of trastuzumab to lapatinib in a prospectively 
defined HER2+ population. 
Treatment of metastatic BC aims at palliating symptoms, prolonging sur-
vival and maintaining good quality of life. So far, study results indicate that 
lapatinib can extended PFS without improving or compromising QoL when 
added to other active treatments for metastatic BC. As long as data for OS 
are missing, it seems that the primary benefit of orally administered la-
patinib is the potential of delaying more aggressive therapies with consider-
able toxicities in a well-defined (preferably by fluorescent in situ hybridiza-
tion [11]) HR+/HER2+ population.  
 
PFS increase by about 5 
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cardiac adverse events 
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no data on OS, no 
changes in QoL 
benefit: delay of more 
aggressive therapies in 
well defined 
HR+/HER2+ patients 
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